Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:35:02 EDT Tue 22 Oct 2024
Enter Symbol
or Name
USA
CA



Q:CLDX - CELLDEX THERAPEUTICS INC - http://www.celldextherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CLDX - Q0.127.65·55.000.128.69+0.441.6820.022,8457,73228.00  29.07  27.5153.18  22.11Oct 21Sep 2515 min RT 2¢

Recent Trades - Last 10 of 7732
Time ETExPriceChangeVolume
19:42:24Q29.291.041
19:10:17Q28.800.553,415
19:03:42Q29.781.533,998
18:58:10Q29.661.412
18:37:05Q28.500.2549
18:36:59Q28.580.334,475
18:35:13Q29.311.064,498
18:34:06Q28.590.3443
16:39:26Q28.300.056
16:20:00Q28.690.44167

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-25 10:45U:CLDXNews ReleaseCelldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
2024-09-16 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
2024-09-12 16:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Upcoming Investor Conferences
2024-08-08 16:01U:CLDXNews ReleaseCelldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-07-29 16:01U:CLDXNews ReleaseCelldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
2024-07-16 08:01U:CLDXNews ReleaseCelldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
2024-06-04 16:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Jefferies Healthcare Conference
2024-06-02 09:01U:CLDXNews ReleaseCelldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
2024-05-15 08:01U:CLDXNews ReleaseCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
2024-05-06 16:01U:CLDXNews ReleaseCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-17 08:01U:CLDXNews ReleaseCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
2024-03-08 07:00U:CLDXNews ReleaseCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2024-03-05 10:30U:CLDXNews ReleaseCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
2024-03-05 10:11U:CLDXNews ReleaseCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-29 21:15U:CLDXNews ReleaseCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
2024-02-28 16:01U:CLDXNews ReleaseCelldex Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-26 07:01U:CLDXNews ReleaseCelldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-24 14:05U:CLDXNews ReleaseCelldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2024-02-06 16:01U:CLDXNews ReleaseCelldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-02-05 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024